Table 2.

Trials evaluating hyperbaric oxygen as radiosensitizer, sorted by publication year

Author	Year	Agent	Dose	n	Radiation regimen	Results
Chang et al. [14]	1977	Hyperbaric oxygen	N/A	80	N/A	18 months survival: 28% (vs 10% atmospheric air) Median OS: 38 weeks (vs 31 weeks)
Kohshi et al. [16]	1996	Hyperbaric oxygen	60 min of 100% O2, 2.5 atm	21 (12)	50–71 Gy in 20–30 fractions	PR or CR in 100% (vs 33% atmospheric air)
		+ Nitrosourea	75 mg/m2 d1 + d36
Beppu et al. [17]	2003	Hyperbaric oxygen	60 min of 100% O2, 2.8 atm	39 (29)	60 Gy in 30 fractions	Median TTP: 38 weeks (GBM)
		+ Nitrosourea	80 mg/m2 d1 + d36
		+ IFN-beta	3 million IU/m2 3 times a week
Ogawa et al. [18]	2003	Hyperbaric oxygen	30–60 min of 100% O2, 2.8 atm	21 (15)	60 Gy in 30 fractions	1‑year OSR: 83% 2‑year OSR: 56% Median TTP: 15 months
		+ Procarbazine	90 mg/m2 d1–14
		+ Nitrosourea	80 mg/m2 d1
		+ Vincristine	0.5 mg/m2 d1 + d8
Ogawa et al. [19]	2006	Hyperbaric oxygen	30–60 min of 100% O2, 2.8 atm	41 (31)	60 Gy in 30 fractions	Median TTP:12.3 months Median OS: 17.3 months
		+ Procarbazine	90 mg/m2 d1–14
		+ Nitrosourea	80 mg/m2 d1
		+ Vincristine	0.5 mg/m2 d1 + d8
Kohshi et al. [21]	2007	Hyperbaric oxygen	60 min of 100% O2, 2.5 atm	25 (11)	Stereotactic gamma-radiation Median of 22 Gy in 8 fractions	Median OS: 11 months (GBM)
Yahara et al. [20]	2017	Hyperbaric oxygen	60–90 min of 100% O2, 2 atm	24	40 Gy in 20 fractions 16 Gy Boost in 8 fractions	Median OS: 22.1 months 2‑year OSR: 46.5%
		+ TMZ	75 mg/m2 daily

n = number of patients included (number of patients with glioblastoma in parentheses if multiple entities were included)